Want to see IN:MEDANTA full AI Analyst Report?
MEDANTA Stock Chart & Stats
₹1216.65
₹16.70(1.57%)
At close: 4:00 PM EST
₹1216.65
₹16.70(1.57%)
Day’s Range― - ―
52-Week Range₹955.20 - ₹1,455.85
Previous CloseN/A
Volume335.07K
Average Volume (3M)17.50K
Market Cap
₹353.45B
Enterprise Value₹337.87B
Total Cash (Recent Filing)₹12.55B
Total Debt (Recent Filing)₹9.45B
Price to Earnings (P/E)63.4
Beta0.67
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.04%
Share Statistics
EPS (TTM)20.90
Shares Outstanding268,867,770
10 Day Avg. Volume39,597
30 Day Avg. Volume17,497
Financial Highlights & Ratios
PEG Ratio2.98
Price to Book (P/B)6.52
Price to Sales (P/S)5.86
P/FCF Ratio-114.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,500.00Price Target Upside23.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)25.75
Revenue Forecast (FY)₹51.66B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained multi-year top-line expansion reflects growing patient volumes, higher occupancy and expanded service mix. This durable demand-driven growth supports scale economics, long-term investment returns and strengthens bargaining power with payers and suppliers over the next several quarters.
Scaled Profitability And Healthy ROERising net income and historically healthy ROE indicate effective capital deployment and operating leverage. Sustained profitability provides internal funding for reinvestment, cushions margin shocks, and supports long-term expansion into higher‑acuity services that drive durable value creation.
Historically Improving LeverageA materially improved leverage profile through 2025 enhances financial flexibility and lowers funding costs, enabling the company to pursue capex, acquisitions or network expansion with less strain. This structural improvement supports resilience across economic cycles.
Bears Say
Negative Free Cash Flow In 2026A shift to negative FCF signals higher capex or working capital needs that weaken near-term liquidity and reduce internal funding for growth. If sustained, negative FCF may force external financing, increase cost of capital, and constrain discretionary investment over coming quarters.
Total Debt Increased In 2026A reversal to rising debt after prior deleveraging reduces financial headroom and raises interest expense risk. Persistent debt growth alongside negative FCF would tighten liquidity, limit strategic optionality and heighten sensitivity to revenue or margin slowdowns.
Margin Volatility And Cost PressureDeclining gross profit amid higher revenue suggests adverse mix or rising input costs. Continued margin volatility undermines predictability of cash generation and ROI, complicates budgeting for capex and expansions, and increases earnings risk across the next several quarters.
Global Health Limited News
MEDANTA FAQ
What was Global Health Limited’s price range in the past 12 months?
Global Health Limited lowest stock price was ₹955.20 and its highest was ₹1455.85 in the past 12 months.
What is Global Health Limited’s market cap?
Global Health Limited’s market cap is ₹353.45B.
When is Global Health Limited’s upcoming earnings report date?
Global Health Limited’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Global Health Limited’s earnings last quarter?
Global Health Limited released its earnings results on May 14, 2026. The company reported ₹5.4 earnings per share for the quarter, beating the consensus estimate of ₹4.528 by ₹0.872.
Is Global Health Limited overvalued?
According to Wall Street analysts Global Health Limited’s price is currently Undervalued.
Does Global Health Limited pay dividends?
Global Health Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of 0.04%. See more information on Global Health Limited dividends here
What is Global Health Limited’s EPS estimate?
Global Health Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Global Health Limited have?
Global Health Limited has 268,867,770 shares outstanding.
What happened to Global Health Limited’s price movement after its last earnings report?
Global Health Limited reported an EPS of ₹5.4 in its last earnings report, beating expectations of ₹4.528. Following the earnings report the stock price went up 1.279%.
Which hedge fund is a major shareholder of Global Health Limited?
Currently, no hedge funds are holding shares in IN:MEDANTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Global Health Limited
Operating throughout India, Global Health Limited, known by its Medanta brand, stands as a prominent multi-specialty tertiary care provider. The company delivers a comprehensive suite of healthcare services, with particular expertise in cardiology, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplantation, as well as kidney and urology treatments. Established in 2004 and headquartered in Gurgaon, India, it operates a network of four hospitals strategically located in Gurugram, Indore, Ranchi, and Lucknow.
MEDANTA Stock 12 Month Forecast
Average Price Target
₹1,500.00
▲(23.29% Upside)
Technical Analysis
Apollo Hospitals Enterprise Limited
―
Aster DM Healthcare Ltd.
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Narayana Hrudayalaya Ltd.
―







